



Believe we can

IMPACT REPORT 2021

prevent  **cancer**[®]
FOUNDATION

A grayscale photograph of a woman with dark hair, smiling and looking towards the right. She is wearing a light-colored top. In the background, there is a blurred image of a medical professional in a white coat, possibly a nurse or doctor, standing near some medical equipment.

Table of Contents

- 1** Letter from Founder and Chairman of the Board
- 2** Back on the Books
- 4** Katie's Story
- 5** Back on the Books Influencers
- 6** Multi-Cancer Early Detection
- 7** Prevent Cancer Advocacy Workshop
- 8** Research Grantees
- 10** Technical Fellowships
- 11** Global Grants
- 12** Community Grants
- 14** Think About the Link
- 15** Too Young for This Sh*t
- 16** Action for Cancer Awareness Awards
- 17** Awesome Games Done Quick
- 18** Prevent Cancer Dialogue
- 19** Quantitative Imaging Workshop
- 20** Prevent Cancer Annual Gala
- 22** Donor Spotlights
- 24** Beneficiary Events
- 25** Foundation in the News
- 26** Social media | Breast Health Education
- 27** preventGEN
- 28** Board of Directors
- 29** Senior Staff
- 30** Medical Advisory Board
- 31** Scientific Review Panel
- 32** Believe we can
- 33** Ways to give

Letter from Founder and Chairman of the Board

Dear Friends,

How are we making an impact on the world around us?

That's the question we've been asking ourselves at the Prevent Cancer Foundation. The past two years have been a turbulent time around the world; at the Foundation, we used this as a time of reflection. We want to be sure we are spending your dollars to make the biggest impact we can on cancer prevention and early detection, through our research, community and global grants; our education campaigns; our conferences and events; and so much more.

That's why we are proud to introduce our first-ever Impact Report. No longer an annual report detailing Foundation activities, the Impact Report tells the story of what we are accomplishing together with your contributions and support.

As we embark on exciting plans for the future, we hope to one day tell the story of a world where no one dies of cancer. Thank you for being our partner as we write the next chapter.

Sincerely,

Carolyn Aldigé

Carolyn Aldigé

Founder and CEO

Gary R. Lytle

Gary R. Lytle

Chairman of the Board of Directors



Time to get screenings *Back on the Books*

As more Americans are vaccinated against the coronavirus, their comfort in going to the doctor and dentist is increasing—but many people still need to reschedule routine cancer screenings. They could be lifesaving! But the third Prevent Cancer Foundation Back on the Books survey shows mixed results for long-term cancer prevention.

Some Americans are going back to their doctors, and we saw a decline in the number of older Americans who missed, postponed or cancelled appointments (34% in December 2020 to 28% in May 2021). But to start with, a significant proportion of adults (27%) are unaware of what cancer screenings are recommended for them—and an even higher number (39%) are not planning to go to future screenings. Minorities were even less aware of what screenings they need than their white counterparts.

The new survey released by the Foundation was fielded one year after the initial May 2020 survey on cancer screening behavior during the pandemic. The results of this survey were the impetus behind the Back on the Books campaign to encourage rescheduling cancelled and postponed cancer screenings.

The Prevent Cancer Foundation continues to share important screening messaging, including tips on how to safely keep doctor appointments and resources for the recommended screenings for an individual's age group, at www.preventcancer.org/backonthebooks.

Percentage of Americans Not Aware of Cancer Screenings & Not Planning to Go

According to a May 2021 survey




27%
Are not aware of
cancer screenings



39%
Are not planning to go to
future screenings

Not Aware of Cancer Screenings Recommended to Them (by Race & Ethnicity)

According to a May 2021 survey



Prevent Cancer Survey, (2021)



Katie's Story

It was a pretty normal Sunday at the end of January 2016 when we noticed something a little abnormal on my left side. I will admit I was past due on scheduling my yearly OB-GYN appointment. I called the doctor on my way to work Monday morning and was scheduled to go in on Tuesday. I left the doctor feeling relieved. I had been fortunate to live a healthy life up to this point, so why would I be worried?

Come Thursday, I was lying on the table with my left arm over my head trying to guess what the radiation oncologist was looking at on the screen. She told me she wanted to do a needle biopsy. I received a call from the doctor Friday telling me I had 'a cancer' (yes, she actually phrased it like that).

In that instant, life as I knew it completely changed. After multiple tests over the next 2 weeks, at age 27 I was diagnosed with Stage 2b Invasive Lobular Carcinoma. I had about one year of intense treatment and am currently undergoing 5-10 years of hormone therapy.

I share this story not in an effort to scare you, but to say that cancer can happen to anyone. Fortunately, there are some simple steps to try and find it early if, heaven forbid, you are diagnosed. One of those is to stay on top of your normal health screenings. It can be easy in such hard and uncertain times to de-prioritize proactive screenings, but it's critical that we don't put these off. If you can take one thing away from my story, I hope you will schedule your next annual checkup or screening. **Early detection really does save lives!**

— Katie Scola

The image shows a woman with blonde hair, wearing a patterned top and multiple necklaces, holding a smartphone. The phone screen displays a social media post with a play button icon and a list of comments. The comments are from users like 'Inghelien@ig' and 'Inghelien@ig', discussing topics related to 'SCARF' and 'SCARF'.





Multi-Cancer Early Detection

Multi-cancer early detection (MCED) tests are blood-based screening tests (also called liquid biopsies) that are designed to identify the presence of cancer for more than one cancer at a time at the earliest possible stages, before noticeable symptoms occur.

Multi-cancer early detection is a groundbreaking new type of cancer screening test that utilizes advances in genomic science and machine learning to transform cancer detection. MCED tests:

- Are designed to detect many types of cancer by looking for cancer signals in the blood.
- Are designed to be complementary to existing screenings and extend the benefits of early detection to catch more cancers in early, more treatable stages.
- Have received breakthrough designations from the Food and Drug Administration (FDA). Their clinical programs continue to advance, as evidenced by data published in peer-reviewed publications.
- Are being developed by many companies in partnership with some of the leading cancer research institutions in America.

The Prevent Cancer Foundation led more than 300 organizations from all 50 states in joining together in a sign-on letter to support the Medicare Multi-Cancer Early Detection Screening Coverage Act of 2021. Our goal is to ensure that when these tests are approved by the FDA, seniors and other Medicare beneficiaries will have access to them.


A diverse array of additional medical, community and public health-focused organizations across the U.S. join with the Prevent Cancer Foundation in applauding the legislation and calling for action on this issue. These organizations provide essential services to cancer patients, offer resources to families and raise awareness of the need to improve prevention and care for a range of different cancers.

In June 2021, the Prevent Cancer Foundation launched an education campaign and ran both print and digital public service ads to raise awareness of multi-cancer early detection testing. A print ad ran in the Washington Post and digital ads ran in The Washington Post, Politico and The Hill. Each digital ad directed individuals to the Prevent Cancer Foundation website on multi-cancer early detection testing. The ads resulted in a 12,116% increase in web traffic from the previous week.

Advocacy Workshop

“By expanding the benefits of early detection to more cancers and more people—especially individuals in racial and ethnic minority groups, individuals with no insurance coverage, and people with complex medical needs and others where screening rates are low and late-stage diagnoses are high—outcomes for cancer patients could also improve.”

—Jody Hoyas



The 2021 Prevent Cancer Advocacy Workshop convened patients, providers, advocacy organizations and other stakeholders to engage in a dialogue around emerging technology in cancer prevention and control. The event featured speakers and breakout sessions focused on patient-centered considerations for multi-cancer early detection (MCED) testing, including access, affordability, acceptance and accountability. Given the Foundation's mission of saving lives across all populations through cancer prevention and early detection, MCED testing has been identified as a priority. Numerous specialty care and advocacy organizations were represented, including the Cancer Policy Institute at the Cancer Support Community, Johns Hopkins Medicine, the Mayo Clinic, the American Cancer Society-Cancer Action Network and Livestrong Cancer Institutes at the Dell Medical School.

Following the Advocacy Workshop, the Prevent Cancer Foundation released a white paper detailing a patient-centered approach to MCED testing. Highlights of the paper include MCED 101; presentation summaries on access, affordability, acceptance and accountability; existing Medicare coverage and legislation in the 117th Congress; and findings and common themes. You can read the white paper and learn more about the Foundation's work on MCED testing at preventcancer.org/early.

Research Grantees

With your help in 2021, the Prevent Cancer Foundation awarded nine promising research grants and fellowships with different areas of focus: cancers of the pancreas, esophagus, liver, lung, skin, prostate, colon-rectum and blood/bone marrow. Our funding helps propel early-career researchers toward larger grants that will expand their work in innovative ways to positively impact people's lives through improved cancer prevention and early detection.



GRANTEE: **Limor Appelbaum, M.D.**

NAMED AWARD: Awesome Games Done Quick

INSTITUTION: Beth Israel Deaconess Medical Center, Boston, Mass.

PROJECT TITLE: Use of medical records and microbiome for predicting pancreatic cancer



GRANTEE: **Julie A. Barta, M.D., A.T.S.F.**

NAMED AWARD: Richard C. Devereaux Outstanding Young Investigator Award

INSTITUTION: Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, Pa.

PROJECT TITLE: Improving lung cancer screening barriers for vulnerable populations



GRANTEE: **Neil Box, Ph.D.**

INSTITUTION: University of Colorado Denver, Anschutz Medical Campus and Denver Campus, Denver, Colo.

PROJECT TITLE: Integrating sun damage indicators in melanoma risk modeling



GRANTEE: **Sigrid Carlsson, M.D., Ph.D., MPH**

NAMED AWARD: Awesome Games Done Quick

INSTITUTION: Memorial Sloan Kettering Cancer Center, New York, N.Y.


PROJECT TITLE: Improving prostate cancer screening using innovative technology



GRANTEE: **Margie Clapper, Ph.D.**

INSTITUTION: The Research Institute of Fox Chase Cancer Center, Philadelphia, Pa.

PROJECT TITLE: Impact of atorvastatin with or without aspirin on colorectal biomarkers in patients with Lynch Syndrome: a pilot study



GRANTEE: **William Grady, M.D.**

NAMED AWARD: The Shure Family Charitable Foundation

INSTITUTION: Fred Hutchinson Cancer Research Center, Seattle, Wash.

PROJECT TITLE: Dysbiotic esophageal microbiomes and esophageal cancer risk



FELLOW: **Natalia Heredia, Ph.D., MPH**

NAMED AWARD: Marcia and Frank Carlucci Charitable Foundation

INSTITUTION: The University of Texas Health Science Center, Houston, Texas

PROJECT TITLE: Culturally tailored lifestyle intervention for Hispanic non-alcoholic fatty liver disease




GRANTEE: **Maro Ohanian, D.O.**

NAMED AWARD: Triad Foundation, LLC

INSTITUTION: University of Texas M.D. Anderson Cancer Center, Houston, Texas

PROJECT TITLE: Detoxification of environmental metals to prevent acute myeloid leukemia



FELLOW: **Aayushi Uberoi, Ph.D.**

NAMED AWARD: Awesome Games Done Quick

INSTITUTION: University of Pennsylvania, Philadelphia, Pa.

PROJECT TITLE: Modulating skin microbiota-host interactions to prevent UV-induced skin cancer

Researcher update: 2019 awardee



GRANTEE: **John McDonald, Ph.D.**

NAMED AWARD: Michele and Drew Figdor Award

INSTITUTION: Georgia Institute of Technology, Atlanta, Ga.

PROJECT TITLE: Noninvasive test for the detection of Type I and Type II ovarian cancer

Ovarian cancer is usually diagnosed in late stages, when treatment may not be successful. Previously, Dr. McDonald's team developed a method to distinguish between healthy women and those with early-stage ovarian cancer. With funding from the Prevent Cancer Foundation, Dr. McDonald and his research team conducted a pilot study to see if this non-invasive method can also distinguish highly-aggressive ovarian cancer from less-aggressive cancer.

Dr. McDonald's research project was completed in August 2021 —and indeed **found that certain metabolites in the blood of ovarian cancer patients appear to accurately distinguish between Type I and Type II ovarian cancers.** Additional machine-learning based analyses are underway to identify the minimum number of specific metabolites that most accurately distinguish between ovarian cancer types.

Dr. McDonald will use these preliminary results for a **larger proposal to the National Institutes of Health (NIH)** to expand the number of patients in the study and go into greater depth on the molecular processes and how they impact the clinical aggressiveness of ovarian cancers. These findings may contribute to more precise diagnosis of early-stage ovarian cancers and novel approaches for treatment. Thank you to all Prevent Cancer Foundation supporters for making Dr. McDonald's research possible.

Technical Fellowships

Awarded in partnership with the Union for International Cancer Control



Roya Dolatkhan, M.D.

Tabriz University of Medical Sciences, Iran

TITLE OF FELLOWSHIP: Accuracy of stool-based tests compared with colonoscopy for diagnosing colorectal cancer and advanced adenomas in northwest Iran

HOST INSTITUTION: National Cancer Institute, Division of Cancer Epidemiology and Genetics, Rockville, Maryland



Bridget Lumbwe, M.Sc.

UNC Global Projects Zambia, Lusaka, Zambia

TITLE OF FELLOWSHIP: Identifying barriers that prevent women with positive CIN2/3 LEEP margins from returning for a repeat loop electrosurgical excision procedure (LEEP), and identifying strategies to address this low adherence to treatments

HOST INSTITUTION: International Agency for Research on Cancer, Lyon, France



Nepomuscene Ndiokubwayo, M.D.

Kamenge University Hospital Center, Bujumbura, Burundi

TITLE OF FELLOWSHIP: La cytologie en milieu liquide pour le dépistage précoce du cancer du col utérin/Liquid cytology for early detection of cervical cancer

HOST INSTITUTION: Centre Hospitalier Universitaire de Cocody, Abidjan, Côte d'Ivoire



Nicaise Ntahondi Kamenge, M.D.

University Hospital Center, Bujumbura, Burundi

TITLE OF FELLOWSHIP: Renforcement des capacités en technique et diagnostics immunohistochimiques des cancers/Capacity building in techniques and immunohistochemical cancer diagnostics

HOST INSTITUTION: Hôpital Général de Grand Yoff, Dakar, Sénégal



Manikanda Nesan Sakthivel, M.D.

Indian Council of Medical Research (ICMR), National Institute of Epidemiology, Chennai, India

TITLE OF FELLOWSHIP: Designing a pre-post intervention trial to assess the impact of community health worker-led counseling and navigation on the uptake of colposcopy among non-compliant women screened positive in a community-based screening program

HOST INSTITUTION: International Agency for Research on Cancer, Lyon, France



Tamar Skhirtladze, M.D., MSPH, MPA

National Screening Center, Tbilisi, Georgia

TITLE OF FELLOWSHIP: Enhancing Screening Services for Early Detection of Cervical Cancer in Georgia

HOST INSTITUTION: International Agency for Research on Cancer, Lyon, France



Global Grants

With funds raised from the Awesome Games Done Quick weeklong videogaming marathon, \$375,000 was awarded in support of high-impact global grants to combat cervical cancer in low-resource areas in Kenya, El Salvador, Nepal and India. The five new projects are aligned with the World Health Organization's (WHO) call for the elimination of cervical cancer by 2030.

We are proud to support these one-year, \$75,000 cervical cancer prevention and early detection grants through our global grants program, which focuses on assessing innovative technologies and delivering services and/or education to improve or expand quality cancer screening or prevention.

ORGANIZATION: Grounds for Health

TITLE: Successful Implementation of HPV Self-Sampling in Rural Kenya

LOCATION: Kenya

Human papillomavirus (HPV) DNA testing is endorsed by the WHO as a preferred screening method to end cervical cancer worldwide. This project will allow Grounds for Health to expand its HPV self-sampling initiative, a widely accepted HPV testing method, as part of their efforts to identify best practices in service delivery in low-resource settings.

ORGANIZATION: Basic Health International

TITLE: Feasibility of Thermal Ablation for Cervical Precancer Treatment

LOCATION: El Salvador

Cervical cancer screening must be linked to effective and timely treatment of precancerous lesions for the best possible outcomes. This project will evaluate thermal ablation, a new portable treatment that could increase access to care for women in remote and hard-to-reach areas.

ORGANIZATION: Basic Health International

TITLE: Shifting PCR Testing Capacity from COVID-19 to Cervical Cancer Prevention

LOCATION: El Salvador

This project investigates the feasibility of a new low-cost, self-collected, rapid HPV screening test that is processed in the same polymerase chain reaction (PCR) machines that were acquired for COVID-19 testing. Same-day screening results in combination with portable cervical precancer treatment have the potential to greatly increase access to cervical cancer prevention for medically-underserved populations.

ORGANIZATION: Cancer Care Nepal

TITLE: A Cervical Cancer Prevention Training Program for Nepal

LOCATION: Nepal

Cervical cancer is the most common cancer among women in Nepal. This project will implement a new program to train nurses and doctors on the necessary screening tests to identify precancerous cervical lesions and treatment procedures to prevent progression to cancer.

ORGANIZATION: Christian Medical College, Vellore, Tamil Nadu

TITLE: Preventing Cervical Cancer Through Low-Cost HPV Testing Approaches in Low-Resource Settings of India

LOCATION: India

Access to cervical cancer screening in India is not widespread. This project will work with community partners to assess the feasibility of using low-cost HPV self-testing as a screening method in three diverse settings (rural poor, urban slums and tribal villages).

“The outputs of our research will contribute to the wider knowledge base informing policy decisions in India on how best to provide national scale up of cervical cancer services for women in poverty.”

—Dr. Rita Isaac, MBBS, MD, MPH, Professor



Community Grants

To advance our bold goal of reducing cancer deaths by 40% by 2035, the Foundation provided \$250,000 this year in support of 10 projects dedicated to increasing cancer prevention and early detection in medically underserved communities across the U.S. The projects were selected through a highly competitive grants process, and each program received a one-year, \$25,000 grant.

Some projects are offering screening for the first time, while others are focused on getting people's screenings "back on the books," because of so many postponed or cancelled appointments due to the pandemic. These projects will have a direct and positive impact on communities across the U.S., from Cheyenne, Wyoming, to Bangor, Maine.

Eastern Maine Medical Center (EMMC) • Bangor, Maine

In partnership with the Bangor Region YMCA Caring Connections program, which supports free mammograms for qualifying patients, EMMC will implement process improvements to increase access to screening for patients who have missed or cancelled mammograms due to COVID-19. The project will focus on vulnerable rural and LGBTQ+ communities.

Equal Hope • Chicago, Ill.

The *Returning to Normal—a Catch-up Cancer Screening Program* will expand Equal Hope's current breast and cervical cancer program, urging 60,000 people to schedule cancer screenings that may have been cancelled or postponed due to COVID-19, and navigating 1,000 medically underserved women directly to screening.

Erie Family Health Center, Inc. • Chicago, Ill.

The *Breast Cancer Continuum of Care Program* at Erie Family Health Centers aims to address the language, cultural, financial and logistical barriers Latinas may face when accessing screening on Chicago's West Side. The project will deliver robust outreach and education and refer more than 2,000 women for mammograms.

Long Island Jewish Medical Center • New Hyde Park, N.Y.

The *Cancer Community Connection Program* will increase access to breast, cervical and colorectal cancer screening for 2,000 medically underserved individuals in New York. The program will also provide 200 people with comprehensive patient navigation that will identify and eliminate logistical, financial, linguistic, psychosocial and other barriers that can challenge access to enhanced screening services.

Syracuse University • Syracuse, N.Y.

Empowering Black Pastors to Amplify Colorectal Cancer Prevention Messages to Underserved Communities is a culturally sensitive, faith-based health education intervention. This project will reach 5,000 high-risk African Americans with colorectal cancer education on risk factors and the importance of prevention and early detection.

The Hmong Institute, Inc. c/o Milwaukee Consortium for Hmong Health • Milwaukee, Wis.

The Milwaukee Consortium for Hmong Health (MCHH) will provide outreach and education to increase screening rates in medically underserved Southeast Asian refugee communities in Milwaukee. The *Saving Lives Through Cancer Education During the Pandemic* project will reach 400 men and women through strong community partnerships.

Vietnamese American Cancer Foundation (VACF) • Fountain Valley, Calif.

In the Vietnamese American community, cancer is a leading cause of death. VACF's *Cancer Education and Patient Navigation Program* will provide 600 Vietnamese Americans with cancer prevention education and will navigate 250 community members to health care, including cancer screenings.

West Virginia University (WVU) • Morgantown, W.Va.

The *WVU Cancer Institute's Mobile Lung Cancer Screening Unit (LUCAS)* will partner with approximately 150 community clinics around West Virginia to provide lung cancer screening to 600 patients. Through the use of the mobile unit, the LUCAS Program will remove financial and structural barriers to screening that exist in rural West Virginia.

Western Carolina Medical Society Foundation • Asheville, N.C.

The *Western North Carolina Colorectal Cancer Screening Initiative* is the only program in its region providing colorectal cancer screening to uninsured individuals. This project will provide stool-based fecal immunochemical test (FIT) screening kits to test for colorectal cancer in 500 uninsured patients.

Wyoming Breast Cancer Initiative Foundation • Cheyenne, Wyo.

This project will allow Wyoming women to receive a mammogram without undue financial burden while still using health care providers in their local community. Through strategically developed partnerships, the Wyoming Breast Cancer Initiative will provide 40 mammograms to medically underserved women in rural areas.

2020 grantee update

ORGANIZATION: VAX 2 STOP CANCER

PROJECT TITLE: Preventing HPV-associated cancers through effective provider education

“This grant could not have been more timely, not only because of Alabama’s high HPV-associated cancer rates but also because of the 1 million doses of the HPV vaccine in the U.S. that have been missed by adolescents with insurance because of COVID.”

— Barbara Schuler, VAX 2 STOP CANCER, Executive Director (2020 grantee)

OUTCOMES:

- VAX 2 STOP CANCER trained 35 health care workers from 11 different pediatric and family practices in a five-county area in central Alabama.
- The project resulted in an average increase of 12% for human papillomavirus (HPV) vaccination rates among those practices.
- Among the trained health care providers, 83% reported an increase in knowledge and self-efficacy for providing a strong and effective recommendation for the HPV vaccine.

In 2020, nearly 2,000 individuals were educated on cancer prevention and nearly 1,000 individuals were screened for cancer.



Think About the Link

Think About the Link is a prevention education campaign to increase public awareness of the connection between certain viruses—HPV, hepatitis B and hepatitis C—and cancer.

The campaign focuses on reaching at-risk populations through a variety of tactics, including celebrity spokespeople, health fairs, digital advertising, advocacy efforts and trusted community and culturally sensitive partnerships to meet people where they are most comfortable.

This year, we partnered with the National Harm Reduction Coalition to reduce hepatitis C diagnoses related to the opioid crisis. We are awarding 20 micro-grants to help harm reduction sites begin or scale up syringe service programs and hepatitis C testing, with the goal of reducing risk and increasing diagnoses of hepatitis C—to ultimately prevent liver cancer. These 2020 grants include harm reduction sites in Georgia, Mississippi, Oklahoma, Pennsylvania, Texas and Wisconsin.

Together with these new harm reduction sites we will be creating new education materials on the importance of hepatitis C testing and the link between untreated hepatitis C and liver cancer.



Too Young for This Sh*t*

Think you're too young for this sh*t? Think again. Colorectal cancer is on the rise in younger adults.


The Prevent Cancer Foundation is educating people ages 30-49 that colorectal cancer is not just an “old person’s disease.” Adults under 50 need to be aware of signs and symptoms so they can advocate for their health.

In 1999, the Prevent Cancer Foundation led the charge to have March declared Colorectal Cancer Awareness Month. In March 2021, the Foundation launched a dedicated digital effort through the top 100 websites targeting adults ages 30-49. The results are impressive:

- Nearly **3 million** impressions
- **22,000** direct clicks to the Too Young for This Sh*t educational web page

The Prevent Cancer Foundation was also an instrumental voice in the efforts to lower the colorectal cancer screening age from 50 to 45.

At the end of 2020, 20 members of Congress joined with Reps. Jamie Raskin (D-Md.) and Rodney Davis (R-Ill.) in a letter to the Department of Health and Human Services in support of the U.S. Preventive Services Task Force (USPSTF) lowering the recommended screening age for colorectal cancer to age 45. Reps. Raskin and Davis used the Foundation’s Gut Check report to emphasize the problem of young-onset colorectal cancer and applaud the new draft guidelines from the USPSTF to begin screening at age 45. These guidelines were finalized in spring of 2021, a move that was celebrated by the Foundation and cancer prevention and early detection advocates everywhere.



Rep. Jamie Raskin



Rep. Rodney Davis

Action for Cancer Awareness Awards



Since 1993, the Congressional Families Cancer Prevention Program's Action for Cancer Awareness Awards luncheon has honored congressional spouses, journalists and other advocates for using their respective platforms to educate the public on cancer prevention and early detection. On September 24, 2020, the Congressional Families Program held a virtual awards ceremony streamed live on Facebook and YouTube. Congressional Families Executive Director Lisa McGovern was proud to enable the presentation of the following awards:



CONGRESSIONAL FAMILIES LEADERSHIP AWARD:

Terry Loeb sack, spouse to then-Rep. Dave Loeb sack (D-Iowa). Ms. Loeb sack, a three-time skin cancer survivor, is a longtime member of the Congressional Families Program and its Advisory Committee.



EXCELLENCE IN CANCER AWARENESS AWARD:

Dr. Ken Jeong, actor/producer/comedian and former practicing physician. Jeong has used his comedy to raise awareness about breast cancer screening following his wife's diagnosis. (She has now been cancer-free for 12 years.)



DISTINGUISHED SERVICE IN JOURNALISM AWARD:

Craig Melvin, "TODAY" Show co-host. Following his brother's colorectal cancer diagnosis, Melvin began to use his platform to raise awareness about the rise of young-onset colorectal cancer, encourage family conversations and highlight the importance of screening.



SPECIAL RECOGNITION AWARD:

Games Done Quick (GDQ), an organization using a novel platform—video games—to raise significant funds for its charitable beneficiaries. GDQ hosts video game marathons and has raised more than \$25 million primarily for two organizations, the Prevent Cancer Foundation and Doctors Without Borders. Through its support of the Foundation, it has brought the message of cancer prevention to a younger, global audience.

The virtual program featured welcome remarks and words of support for the honorees from **House Speaker Nancy Pelosi** and **Republican Leader Kevin McCarthy**.

The Congressional Families Cancer Prevention Program works year-round to equip members and spouses—through educational seminars and webinars, events, and op-eds and social media posts—to bring the message of cancer prevention and early detection back to their communities and constituents. 2021 events included webinars on skin cancer prevention and early detection and breast cancer screening guidelines and disparities.



Awesome Games Done Quick

In January, hundreds of thousands of gamers from around the world (yes, hundreds of thousands!) gathered online to participate in Awesome Games Done Quick (AGDQ) 2021 and raise money for the Prevent Cancer Foundation. The annual weeklong, 24-hour-a-day event is a speedrunning marathon, featuring gamers who compete to complete video games as fast as possible. Fans show their support during the livestream by making donations and sharing how cancer has impacted their lives. Despite being completely virtual this year, the event raised more than \$2.76 million from about 42,000 individual donations.

These funds will support national and global grants for cancer prevention and early detection. Throughout the event, several Prevent Cancer Foundation grant recipients spoke with gamers about their global work made possible by past AGDQ marathons. Games Done Quick has grown from a \$10,000 fundraiser—held in a basement in 2010—to a twice-annual event that typically draws thousands of in-person participants and hundreds of thousands more online to raise millions for selected charities.

With support from passionate gamers, we are well on our way to a world where no one dies of cancer.

During the marathon, the Prevent Cancer Foundation invited participants to share #WhyIAGDQ on social media.

“Cancer took my grandparents, but couldn’t take my mom. Seeing others who love games as much as I do harness that passion to improve the world is an amazing sight and gives me hope that we’ll be able to save so many more from cancer.”

— @GamingBricaBrac, submitted on Twitter



Prevent Cancer Dialogue:

Prevention. Action. Screening

“This award is an encouragement to keep serving the African immigrant community in the best ways that we can.”

— Ify Anne Nwabukwu
African Women's Cancer Awareness Association
Changing Lives, One Woman At A Time
WWW.AWCAA.ORG

The 2021 Prevent Cancer Dialogue was held virtually as a series of three webcasts on April 7 (Innovations in cancer prevention), May 5 (Innovations in early detection of cancer) and June 2 (Progress and challenges in cancer screening).

Dr. Garth Graham, Director and Global Head, Healthcare and Public Health at Google and Head of YouTube Health kicked off the webcasts with his keynote address, “The Digital Revolution in Public Health and Healthcare.” Dr. Graham focused on Google and YouTube’s innovations to improve health disparities. His presentation was followed by a discussion with Molly McCarthy, National Director, U.S. Health Providers & Health Plans for Microsoft, about the role of technology in innovations in public health.

“Thank you for providing perspective on different populations. The facts and figures and findings presented were very eye-opening.”

– 2021 Virtual Dialogue Attendee

The 2021 Dialogue had more than 1,200 individuals registered from:

- 49 states
- several American Indian/Alaska Native groups
- District of Columbia
- Guam
- Puerto Rico
- 18 other countries in Latin America and the Caribbean, Sub-Saharan Africa, East Asia, South Asia and Europe.

2021 Cancer Prevention Laurels Awards:

The 2021 awards were presented virtually to recognize extraordinary work in cancer prevention or early detection, especially in times of COVID-19:

- Cancer Prevention Laurel for National Leadership: David Ahlquist, M.D., Mayo Clinic (posthumous award)
- Cancer Prevention Laurel for Dedication to Community Service: Ify Anne Nwabukwu, African Women’s Cancer Awareness Association
- Cancer Prevention Laurel for Increasing Health Equity through Innovation: Tsu-Yin Wu, Ph.D., MSN, Eastern Michigan University

Quantitative Imaging Workshop XVIII:

Optimizing Thoracic Imaging to Detect and Manage Early Lung Cancer/COPD

The 18th Quantitative Imaging Workshop, held virtually November 4-5, 2021, explored the intersection of quality thoracic imaging and the possible early detection and subsequent clinical intervention of early lung cancer/COPD. In partnership with the American Lung Association, the Foundation brought together thought leaders from across disciplines involved in the global implementation of thoracic CT screening to exchange ideas on exciting new biomedical opportunities that this transformational technology enables, as well as information on the quality, equity and consistency of policy and advocacy for responsible lung cancer, COPD and cardiovascular screening.

Key Issues

Attendees discussed ways to increase the benefit of thoracic CT imaging of individuals with a history of extended tobacco product use—from population health strategies to the inherent challenges in obtaining equitable, quality data. Participants also explored how pre-symptomatic detection of major chronic conditions by low-dose computed tomography (LDCT) may allow more robust support of preventive practices and result in impactful clinical interventions.

James L. Mulshine, M.D., National Leadership Award



Mary Pasquinelli, DNP, APRN, FNP-BC, received this award in recognition of her leadership of the lung cancer screening program at University of Illinois Hospital's federally qualified health center on Chicago's West Side. The award underscored her dedication to delivering screening services to vulnerable populations around the world, while continuing research to enable greater benefit from screening.

Results

Stay tuned for two combined COPD and lung cancer screening protocol guidance documents – one focusing on possible clinical interventions and one on quality image acquisition for COPD and lung cancer.

In 2020, the usual in-person format of the Quantitative Imaging Workshop was replaced by a virtual meeting, held in partnership with the American Lung Association on October 28-30. This allowed for safe global participation of thought leaders. Attendees explored clinical practice recommendations and collaborated with the American Cancer Society National Lung Cancer Roundtable and the Quantitative Imaging Biomarker Alliance of the Radiological Society of North America to discuss how to optimize the precision of image quantitation.

Prevent Cancer Annual Gala:

Season of Splendor



Though our 2020 Virtual Gala was one for the record books, the Prevent Cancer Foundation was thrilled to welcome guests back in person at the National Building Museum on December 1, 2021, for the Prevent Cancer Annual Gala.

HONORED

The 2021 Gala honored His Excellency, the Ambassador of the Republic of Korea, Soo Hyuck Lee and Mrs. Hye Kyung Hwang

PERFORMED

- Rayshun LaMarr, cancer survivor, season 4 semi-finalist, The Voice
- Ali Rogin, cancer “previvor,” producer, PBS
- Sister Hazel, rock band
- Washington Samulnori, traditional Korean percussion group



INSPIRED



Actor, singer and song writer Rayshun LaMarr shared his moving story during the Lighting the Way to Prevention pledge drive. In 2012, he was diagnosed with lymphoma, and battled through two years of extreme medication and chemotherapy. The battle against cancer affected his hearing and voice to the point of temporary loss. Fortunately, Rayshun beat his cancer and regained his beautiful voice—and shared his talents with us at the Gala.



AWARDED

The Foundation recognized Senator Tim Scott and Representative Debbie Dingell with the 2021 Cancer Champion awards.

SUPPORTED

Our sincerest thanks to Gala Co-chairs Nickie Currie, Ted Okon and Susanna Quinn and Dinner Committee Co-chairs Kathryn Kennedy and Lori Reilly for their hard work to make this event possible.

RAISED

The Prevent Cancer Annual Gala shattered the initial \$1.6 million goal. At press time, the event had raised \$1.8 million and counting.

DESIGNED



The stunning décor, a tribute to the Republic of Korea, was designed by board member and weddings and celebrations expert David Tuter. This year marked David's 20th Anniversary of designing a breathtakingly beautiful event for the Foundation.

Donor Spotlights




Jeremy Hardy FitzGerald

"My father died of cancer when I was 10 years old, so I have always been sympathetic of Bo's [Carolyn Aldigé's] founding of the Foundation [in memory of her father]. I happened to pick up the phone the night the doctor called to say my father had died. This was 1950. I remember him saying so clearly, '*I wish there were more we could have done.*' And I think each step the Foundation takes, through education, research and community outreach, is helping do more.

As a cancer survivor myself and a member of the board of directors, it's been one of the things I feel has been most important to me in my life. The Foundation has given me so much more than I have been able to give the Foundation, and I'm so grateful for the experience.

The most encouraging fact is that we hope to reduce cancer deaths by 40% by 2035, and stop cancer before it starts. Read the mission of the Foundation—it's everything we should be doing to help prevent this disease, to have early detection, and to help those with the disease."



Ravi “feardragon” Pareek

“I heard about the Prevent Cancer Foundation through Awesome Games Done Quick (AGDQ), and when I decided to raise money to combat cancer, it was the first organization I thought of.

The community that participated in our fundraiser is the esports community for a game called StarCraft 2. We’ve had members of our community who have battled or are still battling cancer. One of the most notable was the loss of our dear friend, John “TotalBiscuit” Bain.

I think this cause is very near and dear to a lot of us. Cancer treatment is an important area, but even better to me is early detection and prevention before it can take root to minimize the disruption and suffering.

I decided to put together the fundraiser for my 10-year anniversary of getting started in this space. [The work of the Prevent Cancer Foundation] really does mean the world to me and the rest of the StarCraft 2 community.”



Beneficiary Events


“June 19th is my least favorite day of the year. This year, June 19, 2020, marks five years since my mom passed. [In] previous years, I spiral into being an anxious and depressed mess, stuck in a loop reliving the day she died. This year has been different. This year I’m doing something positive with my grief...I’ve put together a charity compilation on my label of cover songs that benefit the Prevent Cancer Foundation, Songs for Moms vol. 1.”

Chris’ story is one we hear all too often. For those impacted by cancer, whether it is your own diagnosis or that of a loved one, the date of diagnosis or loss can feel hard to face. Taking back your day with a new positive memory can be a great way to channel those difficult feelings and associations. Putting together a fundraiser to benefit the Prevent Cancer Foundation is a meaningful way to commemorate that date and turn one of your hardest days into a way to help others so they never have to go through what you did.

“I hope this can be the start of something big and I’m already looking forward to Volume 2 next year!” Chris said.

If you are ready to host your own fundraiser, you can get started in just two easy steps:

1. Go to www.youcanpreventcancer.org to create your personal fundraising page.
2. Share that page with family and friends!



Fundraisers like Chris’ charity compilation are critical to helping the Foundation continue its work to *Stop Cancer Before It Starts!*® Thank you for “taking back the day” with the Prevent Cancer Foundation.

[illegible]


Why It's Important to Get Your Cancer Screenings Back on Track

[illegible]

A screenshot of a web browser displaying an article on the 'rpf' website. The browser's address bar shows 'rpf.com'. The article title is 'Screenings for Cancer Dropped Dramatically During The Pandemic'. Below the title is a sub-header 'COVID-19' and a date '11/11/2020'. The author is 'Dr. Thomas J. Finkelstein, MD, PhD'. The article text begins with 'In the face of the pandemic, routine cancer screening declined by 30 percent...'. The article is categorized under 'COVID-19' and 'Screening'. The page includes a '0 Comments' section and a '0 Likes' section. The article is part of a series of 10 posts, with the first post being the current one. The article is written by Dr. Thomas J. Finkelstein, MD, PhD, and is part of a series of 10 posts. The article is written by Dr. Thomas J. Finkelstein, MD, PhD, and is part of a series of 10 posts.

The image is a screenshot of a Fox News website article. At the top, the Fox News logo is visible on the left, and navigation links like 'Home', 'Live', 'Search', and 'Sign Out' are on the right. The article title is 'Fox News' Jennifer Griffin on Afghanistan, Beating Breast Cancer and 35 Years with the Network'. Below the title is the byline 'By Dan Snierson' and the date '10/24/2016'. A large, central photograph shows Jennifer Griffin, a woman with dark hair, wearing a blue blazer, smiling and holding a microphone. To the left of the main photo is a vertical sidebar with social media sharing icons for Facebook, Twitter, Email, and Print. Below the main photo is a caption: 'Jennifer Griffin, Fox News anchor, speaks during a press conference in Afghanistan.' The article text begins with 'Fox News' Jennifer Griffin returned from a recent assignment in Afghanistan, where she covered the conflict between the Taliban and the U.S. military. She is a co-anchor of the Fox News Sunday program and has been with the network for 35 years. The article mentions her marriage to a former Marine and her battle with breast cancer. It also notes her recent trip to Afghanistan and her plans to continue working for Fox News.

A social media platform for every generation



It seems like everyone and their mother is on social media—but perhaps not the same social media.

The Foundation has long had a presence on Facebook, Twitter, LinkedIn and Instagram, but as the social landscape changes, we recognize a need to evolve and reach a broader audience through more platforms.

Now, you can also find us on TikTok and Discord—so wherever you are hanging out online, you can follow the Foundation and engage with us as we share the latest news in cancer prevention and early detection, updates on how your donation dollars are being spent and stories that remind us why we are working toward a world where no one dies of cancer.

Follow us and join the conversation!



Breast Health Education Guide

Since its launch in 2008, the Breast Health Education for Young Women Facilitator's Guide has been downloaded or shared in 61 countries, as well as in all 50 states, 5 U.S. territories, and the District of Columbia.

Both the English- and Spanish-language guides were updated in 2021 and are designed for interactive group sessions on breast health and breast cancer.

In the last six months, 75 people from the U.S., Ghana, Greece, India, Nigeria, Qatar and South Africa downloaded the facilitator's guide. Out of the surveyed group (N=66), 67% intended to use it to educate a group or a community on breast health, 50% were planning to share with colleagues, 32% wanted to use it as a reference for themselves and 30% wanted to share it with friends and family.



preventGEN

The preventGEN committee provides the perspective of younger generations on cancer prevention and early detection. Committee members collaborate with Foundation staff on ideas for campaigns, programs, concepts and content. Their feedback is instrumental in helping the Foundation extend its mission of saving lives across all populations through cancer prevention and early detection.



Elisabeth Clymer Hockersmith
Texas



Valeria Copello
Florida



Suzanne Hafiz
Illinois



Sonya Jampel
District of Columbia



Monica Kasting
Indiana



Joan Malcolm
California



Gabriela Morales
New Mexico



Mary Nicholas
Washington



Elisa Salazar
Illinois



Megan Sappenfield
Texas



Jane Smith
Utah



Erin Steigleder
Virginia



Alicia Storkamp
Minnesota



Kelly Thomas
Connecticut



Irina Usherenko
Washington



Vanessa Uzoh
Texas

Board of Directors



Carolyn R. Aldigé
Founder and CEO



The Hon. Victor Fazio



William Magner



Gary Lytle
Chairman



Jennifer Griffin



Brandon Parry



Joann Piccolo
Vice-Chairman



Whitfield Crowdon, M.D., FACS



Susanna Quinn



James L. Mulshine, M.D.
Vice-Chairman,
Scientific Director



Charles Houser



Hollyn Kidd Schuemann



Jeremy FitzGerald
Secretary



Joel Jankowsky



Brian Shure



Paul Phaneuf
Treasurer



Mia Spiker Johnson



Pawan Singh



Diane Gasey-Landry



Shabnam Kazmi



Jason Van Pelt

Founding Directors

Alan P. Dye

Hon. Harold Keshishian*

Emeritus Directors

David S. Alberts, M.D.

Gatherine P. Bennett

Margaret Bush

Marcia Myers Carlucci

Elmer E. Huerta, M.D., MPH

Alexine C. Jackson

Brock R. Landry

Sustaining Directors

Betty Alewine

Joyce H. Gates

Lilibet Hagel

Gordon (Don) Hutchins

Marcelle Leahy

Lynne O'Brien

Jean Perin

Andrea Roane

George Swygert

David Tutera

Margaret Vanderhye

Virginia A. Weil

*Deceased

Senior Staff



Carolyn R. Aldigé

Founder and
Chief Executive Officer



Jody Hoyos

President and
Chief Operating Officer



Jennifer Niyangoda

Vice President of
Development and Marketing



Karen Peterson, Ph.D.

Vice President, Programs



Lisa Berry Edwards

Managing Director,
External Affairs



Amy Sokal

Managing Director,
Finance and Administration



Lisa McGovern

Executive Director,
Congressional Families
Cancer Prevention Program

Medical Advisory Board

David (Dave) S. Alberts, M.D.
 Director Emeritus, University of Arizona
 Cancer Center
 Retired Regents Professor of Medicine,
 Pharmacology, Nutritional Sciences, Public
 Health and BIOS
 The University of Arizona College of Medicine

Jasjit S. Ahluwalia, M.D., M.P.H., M.S.
 Professor
 Brown University School of Public Health

Bart Barlogie, M.D., Ph.D.
 Professor of Medicine, Hematology and
 Medical Oncology, Retired
 Ichan School of Medicine Mount Sinai

**Monica M. Bertagnolli, M.D., FACS,
 FASCO**
 Group Chair, Alliance for Clinical Trials in
 Oncology
 Professor of Surgery, Harvard Medical
 School
 Associate Surgeon, Brigham and Women's
 Hospital and Dana-Farber Cancer Institute

Rachel F. Brem, M.D., F.A.C.R., F.S.B.I.
 Professor and Vice-Chair
 Director, Breast Imaging and Interventional
 Center
 Program Leader Breast Cancer, the GW
 Cancer Center
 Founder and Chief Medical Advisor, The
 Brem Foundation
 Department of Radiology
 The George Washington Cancer Center
 George Washington University

Paul A. Bunn Jr., M.D.
 Professor, James Dudley Chair in Cancer
 Research
 University of Colorado Denver School of
 Medicine
 Division of Medical Oncology

Sigrid Carlsson, M.D., Ph.D., MPH.
 Assistant Attending Epidemiologist
 Memorial Sloan Kettering Cancer Center

Kenneth H. Cowan, M.D., Ph.D.
 Director, Fred and Pamela Buffett Cancer
 Center
 University of Nebraska Medical Center

Riccardo Dalla-Favera, M.D.
 Director, Institute for Cancer Genetics
 Irving Cancer Research Center
 Columbia University Medical Center

William S. Dalton, M.D., Ph.D.
 Founder & Executive Chair, M2Gen

Andrew Dannenberg, M.D.
 Henry R. Erle, M.D. – Roberts Family
 Professor of Medicine
 Associate Director of Cancer Prevention, The
 Sandra and Edward Meyer Cancer Center
 Weill Cornell Medicine

Raymond N. DuBois, M.D. Ph.D.
 Dean, College of Medicine
 Medical University of South Carolina

H. Shelton (Shelley) Earp III, M.D.
 Director, Lineberger Comprehensive Cancer
 Center
 University of North Carolina

Stephen B. Edge, M.D., FACS, FASCO
 Vice President, Healthcare Outcomes
 and Policy
 Roswell Park Cancer Institute

Margaret Foti, Ph.D., M.D., (h.c.)
 Chief Executive Officer
 American Association for Cancer Research
 (AACR)

Harold P. Freeman, M.D.
 Chairman Emeritus and Founder
 Ralph Lauren Center for Cancer Care and
 Prevention

Patricia A. Ganz, M.D.
 Distinguished Professor Health Policy &
 Management and Medicine
 UCLA Fielding School of Public Health
 David Geffen School of Medicine at UCLA
 Director, Cancer Prevention & Control
 Research
 Jonsson Comprehensive Cancer Center

David M. Gershenson, M.D.
 Professor, Department of Gynecologic
 Oncology & Reproductive Medicine
 The University of Texas MD Anderson
 Cancer Center

Edward Giovannucci, M.D., Sc.D.
 Professor of Nutrition and Epidemiology
 Harvard T.H. Chan School of Public Health

Anna R. Giuliano, Ph.D.
 Professor and Director of the Center for
 Immunization and Infection Research in
 Cancer
 H. Lee Moffitt Cancer Center and
 Research Institute

Gary E. Goodman, M.D., M.S.
 Staff Oncologist/Joint Member
 Swedish Cancer Institute
 Fred Hutchinson Cancer Research Center

Garth Graham, M.D., MPH
 Director and Global Head, Healthcare and
 Public Health, Google
 Head, YouTube Health

Stanley R. Hamilton, M.D.
 Professor and Head, Division of Pathology
 and Laboratory Medicine
 The University of Texas MD Anderson
 Cancer Center

Claudia Henschke, Ph.D., M.D.
 Professor of Radiology
 Department of Radiology
 Icahn School of Medicine at Mount Sinai

Elmer E. Huerta, M.D., MPH
 Director, Cancer Preventorium
 GW Cancer Center
 Clinical Professor of Medicine
 GW School of Medicine

Derek M. Huffman, Ph.D.
 Associate Professor of Molecular
 Pharmacology and Medicine
 Institute for Aging Research
 Co-Director: CEAC Core
 Albert Einstein College of Medicine

Lovell A. Jones, Ph.D., F.H.D.R
 Adjunct Professor, Department of Health
 Promotion & Community Health Sciences,
 Texas A&M University School of Public
 Health (TAMSPH), College Station, Texas;
 Research Faculty, College of Science &
 Engineering, Texas A&M University Corpus
 Christi; Professor Emeritus, University of
 Texas Distinguished Teaching Professor,
 University of Texas MD Anderson Cancer
 Center; Professor Emeritus, University
 of Texas Graduate School of Biomedical
 Sciences

Karen E. Kim, M.D., M.S.
 Office of Community Engagement and
 Cancer Disparities
 University of Chicago

T. Peter Kingham, M.D., FACS
 Associate Attending Surgeon
 Hepatopancreatobiliary Service
 Department of Surgery
 Director, Global Cancer Disparity Initiatives
 Memorial Sloan Kettering Cancer Center

Ann G. Kulze, M.D.
 Dr. Ann & Just Wellness, LLC

Charles ("Chip") Landen, Jr., M.D., M.S.
 Associate Professor
 University of Virginia Health System
 University of Virginia

Bernard Levin, M.D.
 Professor Emeritus
 The University of Texas
 MD Anderson Cancer Center

Marc E. Lippman, M.D.
 Professor of Oncology and Medicine
 Georgetown Lombardi Comprehensive
 Cancer Center

Scott M. Lippman, M.D.
 Distinguished Professor of Medicine
 Senior Associate Dean and Associate Vice
 Chancellor for Cancer Research and Care
 Chugai Pharmaceutical Chair in Cancer
 University of California, San Diego

Patrick J. Loehrer, Sr., M.D.
 Director, Indiana University
 Melvin and Bren Simon Cancer Center
 Indiana University

John L. Marshall, M.D.
 Professor of Medicine
 Chief, Division of Hematology and Oncology
 MedStar Georgetown University Hospital
 Director, Ruesch Center for the Cure of GI
 Cancers
 Professor of Medicine and Oncology
 Lombardi Comprehensive Cancer Center

Elena Martinez, MPH, Ph.D.
 Professor of Family and Preventive Medicine
 Moores Cancer Center
 University of California, San Diego

Harold L. Moses, M.D.
 Director Emeritus
 Vanderbilt-Ingram Comprehensive Cancer
 Center

Larry Norton, M.D.
 Senior Vice President, Office of the President
 Medical Director, Evelyn H. Lauder Breast
 Center
 Norna S. Sarofim Chair of Clinical Oncology
 Department of Medicine
 Memorial Sloan Kettering Cancer Center

Gilbert S. Omenn, M.D., Ph.D.
 Harold T. Shapiro Distinguished University
 Professor
 Senior Director, Center for Computational
 Medicine & Bioinformatics
 Professor of Computational Medicine &
 Bioinformatics, Internal Medicine, Human
 Genetics and Public Health
 University of Michigan

Darrell S. Rigel, M.D., M.S.
Clinical Professor of Dermatology

John C. Ruckdeschel, M.D.
Ruckdeschel Consulting
Adjunct Professor, University of Mississippi

Kathleen Schmeler, M.D.
Professor, Department of Gynecologic
Oncology and Reproductive Medicine;
Executive Director, Global Oncology, MD
Anderson Network;
Director, MD Anderson Cancer Center and
Lyndon B. Johnson Hospital Colposcopy
Clinics

David Schottenfeld, M.D., M.Sc.
John G. Searle Professor Emeritus of
Epidemiology and Internal Medicine
University of Michigan School of Public
Health
Department of Epidemiology

Karen Sfanos, M.S., Ph.D.
Associate Professor of Pathology
Johns Hopkins University School of Medicine

Erich M. Sturgis, M.D., MPH, FACS
Professor and Vice-Chair of Clinical Affairs
Brown Foundation Endowed Chair
Director, Neck and Thyroid Cancer
Multidisciplinary Program
Baylor College of Medicine

George J. Weiner, M.D.
Director, Holden Comprehensive Cancer
Center
University of Iowa

Richard C. Wender, M.D.
Chair of the Department of Family Medicine
and Community Health
University of Pennsylvania Perelman School
of Medicine

Petra Wilder-Smith, D.D.S., Ph.D.
Director of Dental Programs
Beckman Laser Institute and Medical Clinic
University of California Irvine

Walter C. Willett, M.D., Dr.PH.
Professor of Epidemiology and Nutrition
Harvard T.H. Chan School of Public Health

Stephen C. Yang, M.D.
Associate Vice Chair for Faculty
Development
Professor of Surgery
Johns Hopkins Medicine

Robert C. Young, M.D.
President, RCY Medicine
NCCN Foundation Board of Directors

Scientific Review Panel

James L. Mulshine, M.D. (Co-Chair)
Professor, Internal Medicine
Associate Director, Institute for
Translational Medicine
Rush University Medical Center

Bernard Levin, M.D. (Co-Chair)
Professor Emeritus
University of Texas, MD Anderson Cancer
Center

Christopher Albanese, Ph.D.
Professor of Oncology and Pathology
Director, Preclinical Imaging
Research Laboratory (PIRL)
Executive Director, Center for Translational
Imaging (CTI)
Lombardi Comprehensive Cancer Center
Georgetown University

Rebecca Ashare, Ph.D.
Associate Professor, Department of
Psychiatry
Center for Interdisciplinary Research on
Nicotine Addiction
Senior Fellow, Center for Public Health
Initiatives
Perelman School of Medicine at the
University of Pennsylvania

Janet Audrain-McGovern, Ph.D.
Professor, Department of Psychiatry
Perelman School of Medicine
University of Pennsylvania

David Berrigan, Ph.D., MPH*
Behavioral Research Program
Division of Cancer Control and Population
Sciences
National Cancer Institute
**Dr. Berrigan is serving in his personal
capacity.*

Robert Clarke, Ph.D., D.Sc.
Executive Director, Hormel Institute
University of Minnesota

**Nancy Emenaker, Ph.D., M.Ed., R.D.N.,
L.D., F.A.N.D.**
Program Director, National Cancer
Institute
Nutritional Science Research Group
Division of Cancer Prevention
National Cancer Institute
Stanley Thomas Fricke, Nucl. Eng., Ph.D.
Professor of Radiology and Director of
Medical Physics
Georgetown University Medical Center

Leena Hilakivi-Clarke, Ph.D.
Professor of Food Science and Nutrition
University of Minnesota
Leader of Women's Health Section

Stephen Hursting, Ph.D., MPH
AICR/WCRF Distinguished Professor
Dept. of Nutrition, Nutrition Research
Institute, and the Lineberger
Comprehensive Cancer Center

Brian Lehmann, Ph.D.
Research Associate Professor of
Medicine
Vanderbilt School of Medicine
Vanderbilt-Ingram Cancer Center

Mary Beth Martin, Ph.D.
Professor, Departments of Oncology,
Biochemistry and Molecular Biology
Lombardi Comprehensive Cancer Center
Georgetown University Medical Center

Carola Neumann, M.D.
Associate Professor, Department of
Pharmacology
and Chemical Biology
UPMC Hillman Cancer Center
Magee-Women's Research Institute

Rajasha Rupaimoole, Ph.D.
Scientist II, Precision Molecular Oncology,
Cancer Biology
Bayer U.S. LLC Pharmaceuticals, Bayer
Research & Innovation Center, Tufts
Launchpad Biolabs

Marc D. Schwartz, Ph.D.
Professor, Oncology, Georgetown
University School of Medicine
Associate Director for Population Science,
Georgetown Lombardi Comprehensive
Cancer, Co-Director, Jess and Mildred
Fisher Center for Hereditary Cancer and
Clinical Genomics Research

Peter G. Shields, M.D.
Deputy Director, Comprehensive
Care Center
Professor, College of Medicine
Julius F. Stone Chairman in Cancer
Research
James Cancer Hospital
The Ohio State University Wexner Medical
Center

Andrew G. Sikora, M.D., Ph.D.
Professor of Surgery
Director of Research
Department of Head and Neck Surgery
The University of Texas, MD Anderson
Cancer Center

Kenneth D. Tew, Ph.D., D.Sc.
Chairman Dept. of Cell & Molecular
Pharmacology
John C. West Chair in Cancer Research
Medical University of South Carolina

Danyelle M. Townsend, Ph.D.
Associate Professor, Department of Drug
Discovery and Biomedical Sciences
Director, Analytical Redox Biochemistry
Medical University of South Carolina

Bruce J. Trock, Ph.D.
Director, Division of Epidemiology
Brady Urological Institute
Frank Hinman, Jr. Professor of Urology
Professor of Urology and Oncology
Johns Hopkins University School of
Medicine

Kent E. Vrana, Ph.D.
Elliot S. Vesell Professor
Chair, Department of Pharmacology
Penn State College of Medicine

Zhen Zhang, Ph.D.
Associate Professor, Department of
Pathology and Oncology
Johns Hopkins Medical Institutions



Believe we can

The Prevent Cancer Foundation imagines a world where no one dies of cancer. We remain steadfast in our pursuit of cancer prevention and early detection to save lives across all populations.

We believe we can of reduce cancer deaths by 40% by our 50th anniversary in 2035 by investing:

- \$20 million in innovative research and technologies to detect cancer early and advance multi-cancer screening.
- \$10 million to expand cancer screening and vaccination access to medically underserved communities, bringing hope to those who lack access due to financial, logistical and cultural obstacles.
- \$10 million to educate the public about cancer screening and vaccination options—ensuring everyone, everywhere understands the importance of these opportunities to lead long, healthy lives.

Ways to Give

Your support will **help us save lives** through cancer prevention and early detection research, education, outreach and advocacy—including through campaigns such as “Back on the Books,” which urges everyone to reschedule cancer screenings and other routine health care appointments that were postponed due to the pandemic.

Each year, nearly 1.8 million Americans receive a cancer diagnosis. Together, we can reduce that number.

THROUGH YOUR GENEROSITY, WE CAN CREATE A WORLD WHERE NO ONE DIES OF CANCER.

Help us reduce cancer deaths and support the Foundation today.

- Give monthly: Reliable funding provides consistent support to our researchers, community grantees and more.
- Make a donation: Every dollar or share of stock you give is an investment in our vision and mission.
- Celebrate a loved one: Pay tribute in honor or in memory of someone dear to you by helping others.
- Plan a gift: Include the Foundation in your will, trust or estate plans to support our work for generations to come.
- Double your donation: Ask your employer if they match charitable contributions.
- Sponsor an event: Host your own event (golf tournament, video game marathon, silent auction, casino night) with friends to raise money.

*The mission of the Prevent Cancer Foundation
is saving lives across all populations through
cancer prevention and early detection.*



preventcancer.org



ADDENDUM
2021 FINANCIAL REPORT

PREVENT CANCER FOUNDATION

FINANCIAL STATEMENTS

DECEMBER 31, 2021



Certified Public Accountants

Table of Contents

Independent Auditor's Report

Financial Statements

Statement of Financial Position	5
Statement of Activities	6
Statement of Functional Expenses	7
Statement of Cash Flows	8
Notes to Financial Statements	9 - 21



Certified Public Accountants

Independent Auditor's Report

The Board of Directors
Prevent Cancer Foundation

Qualified Opinion

We have audited the accompanying financial statements of **Prevent Cancer Foundation** (a nonprofit organization), which comprise the statement of financial position as of December 31, 2021, and the related statements of activities, functional expenses, and cash flows for the year then ended, and the related notes to the financial statements.

In our opinion, except for the effects of grants payable described in the Basis for Qualified Opinion section of our report, the financial statements referred to above present fairly, in all material respects, the financial position of **Prevent Cancer Foundation** as of December 31, 2021, and the changes in its net assets and its cash flows for the year then ended in accordance with accounting principles generally accepted in the United States of America.

Basis for Qualified Opinion

As more fully described in Note 6 to the financial statements, **Prevent Cancer Foundation** has included \$900,000 of grants expense in calendar year 2021 that was unconditionally awarded in December 2020. In our opinion, accounting principles generally accepted in the United States of America require that unconditional promises to give are recorded as an expense and liability as of the date the promise to give is made.

We conducted our audit in accordance with auditing standards generally accepted in the United States of America. Our responsibilities under those standards are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of our report. We are required to be independent of **Prevent Cancer Foundation** and to meet our other ethical responsibilities in accordance with the relevant ethical requirements relating to our audit. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Responsibilities of Management for the Financial Statements

Management is responsible for the preparation and fair presentation of the financial statements in accordance with accounting principles generally accepted in the United States of America, and for the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is required to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about **Prevent Cancer Foundation's** ability to continue as a going concern within one year after the date that the financial statements are available to be issued.

Auditor's Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not absolute assurance and therefore is not a guarantee that an audit conducted in accordance with generally accepted auditing standards will always detect a material misstatement when it exists. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Misstatements, including omissions, are considered material if there is a substantial likelihood that, individually or in the aggregate, they would influence the judgment made by a reasonable user based on the financial statements.

In performing an audit in accordance with generally accepted auditing standards, we:

- Exercise professional judgment and maintain professional skepticism throughout the audit.
- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, and design and perform audit procedures responsive to those risks. Such procedures include examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of **Prevent Cancer Foundation's** internal control. Accordingly, no such opinion is expressed.
- Evaluate the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluate the overall presentation of the financial statements.
- Conclude whether, in our judgment, there are conditions or events, considered in the aggregate, that raise substantial doubt about **Prevent Cancer Foundation's** ability to continue as a going concern for a reasonable period of time.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit, significant audit findings, and certain internal control related matters that we identified during the audit.

Kositzka, Wicks and Company

Alexandria, Virginia
July 5, 2022

Prevent Cancer Foundation

Statement of Financial Position December 31, 2021

Assets

Current assets

Cash and cash equivalents	\$ 1,748,270
Grants and pledges receivable	348,261
Investments - general	6,166,816
Prepaid expenses	307,264
	<hr/>
	8,570,611

Property and equipment, net of accumulated depreciation

28,455

Other assets

Investments - donor restricted and board designated funds	9,602,269
Deposits and other assets	131,389
Interests in remainder trusts	285,026
Deferred compensation plan assets	506,139
	<hr/>
	10,524,823
Total assets	<hr/>
	\$ 19,123,889

Liabilities and net assets

Current liabilities

Accounts payable and accrued expenses	\$ 201,114
Grants payable, current	1,286,767
Refundable advances	98,000
Deferred rent	10,351
	<hr/>
	1,596,232

Long-term liabilities

Grants payable, net of current portion	375,000
Deferred compensation plan liabilities	506,139
Total liabilities	<hr/>
	2,477,371

Net assets

Without donor restrictions	14,163,079
With donor restrictions	
Purpose or time restricted	2,205,026
Perpetual in nature	278,413
Total net assets	<hr/>
	16,646,518
Total liabilities and net assets	<hr/>
	\$ 19,123,889

The accompanying independent auditor's report and notes are an integral part of the financial statements.

Prevent Cancer Foundation

Statement of Activities for the year ended December 31, 2021

	Without donor restrictions	With donor restrictions	Total
Support and revenue			
Contributions	\$ 1,645,979	\$ 1,327,752	\$ 2,973,731
Bequests	656,642	-	656,642
In-kind contributions	63,825	-	63,825
Special events	4,992,129	-	4,992,129
Less: Costs of direct benefits to donors	(287,315)	-	(287,315)
SBA Paycheck Protection Program loan forgiveness	374,600	-	374,600
Other income	12,346	-	12,346
Net assets released from restrictions	1,508,360	(1,508,360)	-
	<u>8,966,566</u>	<u>(180,608)</u>	<u>8,785,958</u>
Expenses			
Program services			
Research	1,750,922	-	1,750,922
Education and public awareness	3,705,317	-	3,705,317
Community outreach	927,823	-	927,823
Supporting services			
Management and general	710,443	-	710,443
Fundraising	1,174,197	-	1,174,197
	<u>8,268,702</u>	<u>-</u>	<u>8,268,702</u>
Change in net assets before investment and other income	697,864	(180,608)	517,256
Investment and other income	<u>1,460,618</u>	<u>136,434</u>	<u>1,597,052</u>
Change in net assets	2,158,482	(44,174)	2,114,308
Net assets, beginning of period	<u>12,004,597</u>	<u>2,527,613</u>	<u>14,532,210</u>
Net assets, end of period	<u>\$ 14,163,079</u>	<u>\$ 2,483,439</u>	<u>\$ 16,646,518</u>

The accompanying independent auditor's report and notes are an integral part of the financial statements.

Prevent Cancer Foundation

Statement of Functional Expenses for the year ended December 31, 2021

	Program services				Supporting services			Cost of direct benefits to donors	Total expenses
	Research	Education and public awareness	Community outreach	Total	Management and general	Fundraising	Total		
Accounting and auditing	\$ -	\$ -	\$ -	\$ -	\$ 27,500	\$ -	\$ 27,500	\$ -	\$ 27,500
Agency fees	-	86,500	-	86,500	-	-	-	-	86,500
Audio, staging, and entertainment	-	11,751	-	11,751	-	57,968	57,968	4,375	74,094
Advertising and list rentals	213	142,769	161	143,143	536	9,017	9,553	-	152,696
Bank charges	-	-	-	-	4,396	-	4,396	-	4,396
Catering	-	14,339	-	14,339	-	-	-	115,558	129,897
Computer services	261	70,652	198	71,111	1,429	5,782	7,211	-	78,322
Consultant fees	-	91,435	-	91,435	6,120	-	6,120	-	97,555
Credit card discount expense	245	847	-	1,092	89,666	4,114	93,780	-	94,872
Delivery and shipping	87	2,792	66	2,945	3,467	7,766	11,233	-	14,178
Depreciation	783	7,364	593	8,740	1,970	2,342	4,312	-	13,052
Design and layout	-	4,431	-	4,431	11,500	8,700	20,200	-	24,631
Equipment lease	903	8,487	683	10,073	2,270	3,115	5,385	-	15,458
Gifts, contributions, and awards	35	1,995	27	2,057	1,889	1,091	2,980	-	5,037
Grants	1,490,668	149,990	757,099	2,397,757	-	-	-	-	2,397,757
Honorariums	6,000	250	7,300	13,550	-	1,000	1,000	-	14,550
Insurance	13,863	131,354	10,493	155,710	34,865	41,452	76,317	-	232,027
Legal	1,146	10,775	867	12,788	2,882	3,426	6,308	-	19,096
Maintenance and storage	161	3,255	122	3,538	2,163	480	2,643	-	6,181
Meals and meetings	60	1,552	91	1,703	2,389	285	2,674	-	4,377
Media services	-	970,162	-	970,162	-	-	-	-	970,162
Membership dues and subscriptions	437	11,307	3,790	15,534	4,810	1,416	6,226	-	21,760
Payroll taxes and processing	11,332	106,556	8,577	126,465	28,500	33,884	62,384	-	188,849
Printing and supplies	205	16,401	155	16,761	9,057	17,602	26,659	-	43,420
Professional services	43,424	126,758	4,713	174,895	15,498	404,266	419,764	-	594,659
Promotional materials	-	-	-	-	-	3,174	3,174	-	3,174
Rent	16,600	156,088	12,564	185,252	41,748	49,635	91,383	-	276,635
Retirement	6,308	59,315	4,774	70,397	15,865	18,862	34,727	-	105,124
Salaries	145,885	1,371,719	110,415	1,628,019	366,885	436,200	803,085	-	2,431,104
Site rental	30	283	23	336	700	90	790	23,000	24,126
Software and support	5,624	15,423	75	21,122	12,134	31,895	44,029	-	65,151
Taxes, licenses, and registration fees	231	3,145	175	3,551	5,765	1,590	7,355	-	10,906
Telephone and internet	934	8,778	707	10,419	2,348	2,791	5,139	-	15,558
Temporary services	4,254	40,007	3,220	47,481	10,700	17,999	28,699	-	76,180
Training	364	3,421	275	4,060	915	1,088	2,003	-	6,063
Travel and transportation	869	14,710	660	16,239	2,476	6,048	8,524	-	24,763
	1,750,922	3,644,611	927,823	6,323,356	710,443	1,173,078	1,883,521	142,933	8,349,810
In-kind contributions									
Media services	-	60,275	-	60,275	-	-	-	-	60,275
Other	-	431	-	431	-	1,119	1,119	-	1,550
Contributions for special events	-	-	-	-	-	-	-	144,382	144,382
Total expenses by function	1,750,922	3,705,317	927,823	6,384,062	710,443	1,174,197	1,884,640	287,315	8,556,017
Less expenses included with revenues on the statement of activities									
Cost of direct benefits to donors	-	-	-	-	-	-	-	(287,315)	(287,315)
Total expenses included in the expense section on the statement of activities	\$ 1,750,922	\$ 3,705,317	\$ 927,823	\$ 6,384,062	\$ 710,443	\$ 1,174,197	\$ 1,884,640	\$ -	\$ 8,268,702

The accompanying independent auditor's report and notes are an integral part of the financial statements.

Prevent Cancer Foundation

Statement of Cash Flows for the year ended December 31, 2021

Cash flows from operating activities

Change in net assets	\$ 2,114,308
Adjustments to reconcile change in net assets to net cash from operating activities	
Depreciation	13,052
Realized and unrealized gains on investments and change in value of interest in remainder trusts	(1,182,126)
Donated stock	(99,890)
Proceeds from sale of donated stock	99,890
SBA Paycheck Protection Program loan forgiveness	(374,600)
(Increase) decrease in operating assets	
Grants and pledges receivable	(235,341)
Prepaid expenses	(102,546)
Deposits	(67,253)
Deferred compensation plan assets	(98,417)
Increase (decrease) in operating liabilities	
Accounts payable and accrued expenses	99,128
Grants payable	814,284
Refundable advances	(45,000)
Deferred rent	(27,844)
Deferred compensation plan liabilities	98,417
Net cash provided by operating activities	<u>1,006,062</u>

Cash flows from investing activities

Purchase of property and equipment	(9,950)
Proceeds from sale of investments	32,227
Purchase of investments	<u>(346,292)</u>
Net cash used in financing activities	<u>(324,015)</u>

Net change in cash and cash equivalents

682,047

Cash and cash equivalents, beginning of period

1,066,223

Cash and cash equivalents, end of period

\$ 1,748,270

Supplemental disclosure of cash flow information

Cash paid for interest	\$ -
Income taxes paid	<u>\$ -</u>

The accompanying independent auditor's report and notes are an integral part of the financial statements.

Prevent Cancer Foundation

Notes to Financial Statements December 31, 2021

1. Organization

Prevent Cancer Foundation (the Foundation) was incorporated in Virginia in 1985 as a non-stock corporation. The Foundation provides support for cancer prevention, research, education and community outreach programs nationwide and plays a pivotal role in developing a body of knowledge that is a basis for important prevention and early detection strategies. The Foundation focuses its resources on those cancers – including lung, breast, prostate, colorectal, cervical, skin, oral and testicular – that can be prevented through lifestyle changes or detection and treatment in the early stages.

The Foundation's sources of revenue include contributions, bequests, in-kind contributions and special events.

2. Significant accounting policies

Basis of accounting

The financial statements of the Foundation are prepared using the accrual method of accounting in conformity with accounting principles generally accepted in the United States of America (U.S. GAAP).

Use of estimates

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Cash and cash equivalents

For purposes of the statement of cash flows, the Foundation considers all cash and unrestricted highly liquid investments with an initial maturity of three months or less to be cash equivalents. It is the Foundation's policy not to classify certificates of deposit as cash and cash equivalents.

Grants and pledges receivable

Grants and pledges receivable are stated at the amount management expects to collect from outstanding balances. Management provides for probable uncertain amounts through a provision for bad debt expense and an adjustment to a valuation allowance.

Investments

Investments are measured at fair value in the statement of financial position based on publicly available market data obtained from services independent of the Foundation. Investment income or loss (including gains and losses on investments, interest, dividends, and investment fees) is included in the statement of activities as increases or decreases in net assets without donor restrictions unless the income or loss is restricted by donor or law. Money market and short-term investment funds, held as a portion of the Foundation's investment portfolio, are classified as investments and are not considered to be cash equivalents for purposes of cash flows.

Property and equipment

Property and equipment are reported at cost. The Foundation capitalizes purchases over \$1,000. Depreciation is computed using the straight-line method over the estimated useful lives of the assets which range from three to ten years. Upon the retirement or disposal of assets, the cost and accumulated depreciation are eliminated from the respective accounts and the resulting gain or loss is included in revenue or expenses. Expenditures for maintenance and repairs are charged to expenses as incurred.

See independent auditor's report.

Prevent Cancer Foundation

Notes to Financial Statements December 31, 2021

Compensated absences

Employees of the Foundation are entitled to paid vacation depending on job classification, length of service and other factors. As of December 31, 2021, estimated compensated absences of \$83,422 are included in accounts payable and accrued expenses in the accompanying statement of financial position.

Other financial assets and liabilities

Financial assets with carrying values approximating fair value include cash and cash equivalents, grants and pledges receivable, and prepaid expenses. Financial liabilities with carrying values approximating fair value include accounts payable and accrued expenses, deferred rent, refundable advances, and grants payable. The carrying value of these financial assets and liabilities approximates fair value due to their short maturities and any associated interest rates approximate current market rates.

Donor restrictions

Net assets, revenues, gains, and losses are classified based on the existence or absence of donor or grantor imposed restrictions. Accordingly, net assets and changes therein are classified and reported in two categories as described below.

Net assets without donor restrictions are net assets available for use in general operations and not subject to donor restrictions. The governing board has designated, from net assets without donor restrictions, net assets for a board-designated endowment fund..

Net assets with donor restrictions are net assets subject to donor-imposed restrictions. Some donor-imposed restrictions are temporary in nature, such as those that will be met by the passage of time or other events specified by the donor. Other donor-imposed restrictions are perpetual in nature, where the donor stipulates that resources be maintained in perpetuity. Donor-imposed restrictions are released when a restriction expires, that is, when the stipulated time has elapsed, when the stipulated purpose for which the resource was restricted has been fulfilled, or both.

Support and revenue

Contributions received and unconditional promises to give are measured at their fair values and are reported as an increase in net assets. The Foundation reports gifts of cash and other assets as restricted support, if they are received with donor stipulations that limit the use of the donated assets, or if they are designated as support for future periods. When a donor restriction expires, that is, when a stipulated time restriction ends or purpose restriction is accomplished, net assets with donor restrictions are reclassified to net assets without donor restrictions and reported in the statement of activities as net assets released from restrictions. Donor-restricted contributions whose restrictions are met in the same reporting period are reported as support without restrictions.

Refundable advances consisted of contributions received that are conditional upon the occurrence of a specific event. Refundable advances as of December 31, 2021 consisted of \$18,000 for the Gala special event and \$80,000 for the Awesome Games Done Quick event. The Awesome Games Done Quick event was held and conditions were met in January 2022. The Gala is scheduled to be held in the fall 2022, at which time conditions will be met and revenue will be recognized. Refundable advances as of December 31, 2020 consisted of \$18,000 for the Gala special event, \$30,000 for the Awesome Games Done Quick event, and \$15,000 for the Advocacy Workshop. The events were held in 2021, at which time the conditions were met and revenue was recognized.

See independent auditor's report.

Prevent Cancer Foundation

Notes to Financial Statements December 31, 2021

Sources of revenue from contracts with customers include an exchange element of tickets purchased for the Foundation's special events and conference registration fees. All sources of revenue from contracts with customers are recognized at the point in time when the event occurs. For the year ended December 31, 2021, the total exchange portion of tickets for the special events was \$107,250, and conference registration fees totaled \$6,522. As of December 31, 2021, there were no performance obligations or contract liabilities remaining.

In-kind goods and services

The Foundation receives donations in the form of free media services that would otherwise be purchased in the normal course of business. Total in-kind media services were \$60,275 for the year ended December 31, 2021. Donated goods are valued based on comparable market rates and donor valuations. The Foundation also receives services and donated goods in connection with special events. These donations are included in both special event revenue and direct expenses on the accompanying statement of activities.

In addition, a substantial number of volunteers donate time to Prevent Cancer Foundation's program services and special events. These donated services are not reflected in the financial statements since the services do not require specialized skills as defined by U.S. GAAP.

Interests in remainder trusts

The Foundation has been named as beneficiary under a split-interest agreement, which are charitable remainder trusts. Irrevocable split-interest agreements are recorded as revenue when the trust agreements are executed. Revenue from the split-interest agreements is based on the fair value of the expected cash flows to be received by the Foundation. The change in value of interests in remainder trusts was \$24,922 for the year ended December 31, 2021.

Advertising costs

Advertising costs are expensed as incurred.

Concentrations of credit and market risk

Financial instruments that potentially expose the Foundation to concentrations of credit and market risk consist primarily of cash equivalents and investments.

At period-end and throughout the period, the Foundation's cash balances may exceed federally insured limits. Cash and cash equivalents are maintained at high-quality financial institutions. The Foundation has not experienced any losses on its cash equivalents and management does not believe this result in any significant credit risk. FDIC insurance on interest bearing accounts is \$250,000 per depositor, per insured bank. At December 31, 2021, the Foundation's cash balances were approximately \$1,437,584 in excess of federal deposit insurance coverage.

In general, investments are exposed to various risks, such as interest rate, credit, and overall market volatility risk. Due to the level of risk associated with certain investments, it is reasonably possible that changes in the values of investments will occur in the near term and that such changes could materially affect amounts reported in future statements of activities. Management believes that the Foundation's investments do not represent significant concentrations of market risk as the Foundation's investment portfolio is adequately diversified among issuers.

Prevent Cancer Foundation

Notes to Financial Statements December 31, 2021

Income taxes

The Foundation is exempt from federal income tax as a non-profit organization described in Section 501(c)(3) of the Internal Revenue Code and is classified as an organization other than a private foundation. The Organization did not have a liability for unrelated business income for the year ended December 31, 2021.

The material jurisdictions subject to potential examination by taxing authorities include the U.S. and Virginia. The Foundation has no uncertain tax positions that qualify for either recognition or disclosure in the financial statements. Tax years that remain subject to examination by the IRS are fiscal years 2018 through 2021.

Upcoming accounting pronouncements

The FASB has issued ASU 2016-02, which requires lessees to recognize on the balance sheet the assets and liabilities for the rights and obligations created by leases with terms greater than 12 months. ASU 2016-02 is effective for annual reporting periods beginning after December 15, 2021. The Foundation plans to adopt the standard on its effective date, which for the Foundation is January 1, 2022.

The FASB has issued ASU 2020-07, which clarifies the presentation and disclosure of contributed nonfinancial assets, which include tangible property, intangible items, and specialized services. Upon implementation, nonprofits will be required to show in-kind contributions of nonfinancial assets as a separate line, apart from cash contributions, on the statement of activities, along with qualitative information about how the organization either monetized or utilized the assets and a description of the valuation techniques used to arrive at the fair value of the assets at initial recognition. ASU 2020-07 is effective for annual reporting periods beginning after June 15, 2021. The Organization plans to adopt the standard on its effective date, which for the organization is January 1, 2022, and is evaluating the impact of this statement.

3. Grants and pledges receivable

Grants and pledges receivable consisted of the following as of December 31, 2021:

Pledges - Combined Federal Campaign	\$ 22,752
Grants and other pledges receivables	335,508
Allowance for uncollectible amounts	(10,000)
	<u>\$ 348,260</u>

Management has estimated the collectability of the remaining outstanding balances from CFC campaigns and recorded an allowance for uncollectible amounts based on historic collections. The entire balance of grants and pledges receivables as of December 31, 2021 is expected to be collected in less than one year.

Prevent Cancer Foundation

Notes to Financial Statements December 31, 2021

4. Investments

Investments valued at fair value are summarized as follows at December 31, 2021:

Cash and money market funds	\$	2,659,013
Fixed income		3,866,530
Equities		6,069,081
Mutual funds		3,680,600
Fair value per statement of financial position	\$	<u>16,275,224</u>

Investment and other income consisted of the following for the year ended December 31, 2021:

Realized and unrealized gains and change in value of interest in remainder trusts	\$	1,182,126
Interest and dividend income		481,744
Investment fees		(66,818)
	\$	<u>1,597,052</u>

5. Property and equipment

Property and equipment consisted of the following at December 31, 2021:

Office furniture and equipment	\$	189,259
Less: accumulated depreciation		(160,804)
Property and equipment, net	\$	<u>28,455</u>

6. Grants awarded

The Foundation recorded grants expense during the year ended December 31, 2021 totaling \$2,397,757. Adjustments to reflect differences between the award and actual payments are made in the year the final payment is made. Grants recorded but unpaid amounted to \$1,661,767 as of December 31, 2021.

The Foundation intended to award \$900,000 of grants in January 2021. However, the award notifications were inadvertently sent to the grant recipients in December 2020. The Organization has included \$900,000 of grants expense in calendar year 2021 that was unconditionally awarded in December 2020. Accounting principles generally accepted in the United States of America require that unconditional promises to give are recorded as an expense and liability as of the date the promise to give is made. If recorded when awarded, grants expense would be reduced by \$900,000 in the accompanying Statement of Functional Expenses and net assets without donor restrictions as of the beginning of the year would be reduced by \$900,000 in the accompanying Statement of Activities.

See independent auditor's report.

Prevent Cancer Foundation

Notes to Financial Statements December 31, 2021

7. In-kind contributions

In-kind contributions for the year ended December 31, 2021 consisted of the following:

Public service announcements	\$	60,275
Printing discount		1,550
Other assets		2,000
Contributions for special events		
Design services		85,000
Food and beverage		59,382
	\$	<u>208,207</u>

8. Special events

The Foundation sponsors several special events during the year. The purpose of these events is to raise public awareness about cancer as well as to raise funds to further the Foundation's purpose. A summary of special events for the year ended December 31, 2021 is as follows:

	Revenue	Direct benefit expenses	Other expenses	Net
Gala	\$ 2,091,226	\$ 287,315	\$ 199,697	\$ 1,604,214
Awesome Games	2,900,903	-	263,162	2,637,741
	<u>\$ 4,992,129</u>	<u>\$ 287,315</u>	<u>\$ 462,859</u>	<u>\$ 4,241,955</u>

9. Commitments

The Foundation leases office space in Alexandria, Virginia. The lease expired on April 30, 2022. The unamortized portion of the cumulative difference between the actual rent paid and the straight line rent is reflected as deferred rent liability in the accompanying statement of financial position.

Rent expense for the year ended December 31, 2021 was \$276,636.

During 2021, the Foundation entered into a new lease for office space in Alexandria, Virginia beginning May 1, 2022. The term of the lease is 134 months and the base monthly rent is \$19,483.

Future minimum rentals due under this agreement are as follows as of December 31, 2021:

2022	\$	265,967
2023		238,102
2024		244,632
2025		251,360
2026		258,285
2027 and thereafter		1,860,509
	\$	<u>3,118,856</u>

See independent auditor's report.

Prevent Cancer Foundation

Notes to Financial Statements December 31, 2021

In November 2021, the Foundation entered into a contract with Games Done Quick, LLC to take part in the Awesome Games Done Quick event. The Foundation must pay the costs of staff and contractors used to develop the event. As of December 31, 2021, the Foundation had paid \$250,000 of those costs, which is included with prepaid expenses on the statement of financial position. An additional \$180,454 is to be paid in 2022. For the year ended December 31, 2021, approximately 33% of the Foundation's support and revenue has been derived from the Awesome Games special event. Any changes in the benefitting charity in future years would have a significant impact on Prevent Cancer Foundation.

10. Retirement plan

The Foundation maintains a 401(k) plan. The Foundation makes contributions on behalf of employees in amounts ranging from 3% to 4% of an employee's salary. Contributions in the amount of \$85,624 were made for the year ended December 31, 2021.

The Foundation adopted a 457(b) plan in 2007. Only employees within a select group of management or highly compensated employees chosen by the Board of Directors are eligible to participate. Contributions are made at the sole discretion of the Foundation and do not need to be uniform among all participants. For the year ended December 31, 2021, the President was the only participant in the plan. Contributions in the amount of \$19,500 were made on her behalf for the year ended December 31, 2021. Fair market value of the plan was \$506,139 as of December 31, 2021.

11. Net assets with donor restrictions

Net assets are restricted for specific events as well as for future periods. Net assets with donor restrictions as of December 31, 2021 were as follows:

	December 31, 2020	Additions	Releases	December 31, 2021
Restricted to future periods				
Contributions receivable for the Combined Federal Campaign	\$ 42,868	\$ 22,752	\$ 42,869	\$ 22,751
Interest in remainder trusts	260,104	24,922	-	285,026
	<u>302,972</u>	<u>47,674</u>	<u>42,869</u>	<u>307,777</u>
Restricted for specific activities or purpose				
Think About the Link Campaign	362,500	100,000	214,697	247,803
Educational Campaigns	172,050	1,085,000	1,058,099	198,951
Research Grants	162,695	80,000	162,695	80,000
Celebremos Grants	30,000	40,000	30,000	40,000
Sarah Howard fund	604,148	-	-	604,148
	<u>1,331,393</u>	<u>1,305,000</u>	<u>1,465,491</u>	<u>1,170,902</u>
Endowment earnings subject to spending policy and appropriation	614,835	111,512	-	726,347
Donor-restricted endowment subject to a perpetual restriction	278,413	-	-	278,413
	<u>\$ 2,527,613</u>	<u>\$ 1,464,186</u>	<u>\$ 1,508,360</u>	<u>\$ 2,483,439</u>

See independent auditor's report.

Prevent Cancer Foundation

Notes to Financial Statements December 31, 2021

12. Endowment and board-designated funds

The Foundation has three individual funds established for the purpose of funding research grants and community education (the Funds). The Funds include both donor-restricted funds and funds designated by the Board of Directors to function as endowments. The donor-restricted endowment fund was established for the purpose of providing income to support the Foundation's research grant programs. As required by U.S. GAAP, net assets associated with endowment funds, including funds designated by the Board of Directors to function as endowments are classified and reported based on the existence or absence of donor-imposed restrictions.

Interpretation of Relevant Law

The Virginia Uniform Prudent Management of Institutional Funds Act (UPMIFA) requires the preservation of the fair value of the original gifts as of the gift date of the donor-restricted endowment funds absent explicit donor stipulations to the contrary. The Foundation classifies as net assets with donor restrictions perpetual in nature (a) the original value of gifts donated to the permanent endowment, (b) the original value of subsequent gifts to the permanent endowment, and (c) accumulations to the permanent endowment required to be made by explicit directions in the applicable donor gift instrument at the time the gift is added to the fund.

The remaining portion of the donor-restricted endowment fund that is not classified in net assets with restrictions perpetual in nature is classified as net assets with donor restrictions subject to expenditure for a specific purpose until those amounts are appropriated for expenditure by the organization in a manner consistent with the standard of prudence prescribed by UPMIFA. In accordance with UPMIFA, the Foundation considers the following factors in making a determination to appropriate or accumulate additions to donor-restricted endowment funds:

1. The duration and preservation of the fund
2. The purposes of the Foundation and the donor-restricted endowment fund
3. General economic conditions
4. The possible effects of inflation and deflation
5. The expected total return from income and the appreciation of investments
6. Other resources of the Foundation
7. The investment policies of the Foundation

UPMIFA applies only to donor-restricted endowment funds and not to board-designated funds.

Return Objectives and Risk Parameters

The Foundation has adopted investment and spending policies that attempt to provide a predictable stream of funding to programs supported by its Funds while seeking to maintain the purchasing power of the assets. Fund assets include those assets of donor-restricted funds that the Foundation must hold in perpetuity as well as board-designated funds. Under the policy, as approved by the Board of Directors, the assets are invested in a manner that is intended to maximize current return and provide growth and income that at a minimum exceeds inflation for the current year. Actual returns in any given year may vary from this amount.

Strategies employed for achieving objectives

To satisfy its long-term rate-of-return objectives, the Foundation relies on a total return strategy in which investment returns are achieved through both capital appreciation (realized and unrealized) and current yield (interest and dividends). The Foundation targets a diversified asset allocation that places an equal emphasis on equity-based investments and fixed-income mutual funds to achieve its long-term return objectives within prudent risk constraints.

See independent auditor's report.

Prevent Cancer Foundation

Notes to Financial Statements December 31, 2021

Spending policy and how the investment objectives relate to spending policy

The amounts appropriated for distribution by the Foundation vary each year depending on their program needs. Amounts distributed from the Board designated funds are authorized by the Board of Directors and are transferred into the Foundation's operating cash accounts for use during the year. Over the long term, the Foundation expects the current spending policy to allow its Funds to grow and to maintain the Foundation's objective to maintain the purchasing power of the Fund assets held in perpetuity as well as to provide additional real growth through new gifts and investment return.

Net asset composition by type of fund

The net assets consisted of the following as of December 31, 2021:

	Without donor restrictions	With donor restrictions	Total
Donor-restricted endowment funds	\$ -	\$ 1,004,760	\$ 1,004,760
Board-designated endowment funds	8,597,509	-	8,597,509
	<u>\$ 8,597,509</u>	<u>\$ 1,004,760</u>	<u>\$ 9,602,269</u>

Changes in endowment and board-designated funds

The net activity consisted of the following:

	Without donor restrictions	With donor restrictions	Total
Endowment funds as of December 31, 2020	\$ 7,639,570	\$ 893,248	\$ 8,532,818
Investment return, net	957,939	111,512	1,069,451
Contributions	-	-	-
Appropriation of endowments	-	-	-
Endowment funds as of December 31, 2021	<u>\$ 8,597,509</u>	<u>\$ 1,004,760</u>	<u>\$ 9,602,269</u>

Funds with deficiencies

From time to time, the fair value of assets associated with individual donor-restricted endowment funds may fall below the level that the donor or UPMIFA requires the Foundation to retain as a fund of perpetual duration. There were no such deficiencies as of December 31, 2021.

See independent auditor's report.

Prevent Cancer Foundation

Notes to Financial Statements December 31, 2021

13. Fair value of financial instruments

The Foundation utilizes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring inputs that are most observable be used when available. Observable inputs are inputs that are independently derived and based on observable market data. Unobservable inputs are inputs that cannot be sourced from a broad active market. The input hierarchy is broken down into three levels based on the degree to which the exit price is independently observable or determinable as follows:

Level 1 – Valuation based on quoted market prices in active markets for identical assets or liabilities. Since valuations are based on quoted prices that are readily and regularly available in an active market, valuation of these products does not entail a significant degree of judgment. Examples include equity securities and publicly traded mutual funds that are actively traded on a major exchange or over-the-counter market.

Level 2 – Valuation based on quoted market prices of investments that are not actively traded or for which certain significant inputs are not observable, either directly or indirectly, such as municipal bonds. The fair value of municipal bonds is estimated using recently executed transactions, bid/asked prices and pricing models that factor in, where applicable, interest rates, bond spreads and volatility.

Level 3 – Valuation based on inputs that are unobservable and reflect management's best estimate of what market participants would use as fair value. Examples include limited partnerships and private equity investments.

The following methods and assumptions were used to estimate the fair value of each class of financial instruments:

Cash and cash equivalents: The carrying value is considered to be a reasonable estimate of the fair value.

Interest in remainder trusts: The Foundation has interests in irrevocable charitable remainder trusts for which it does not act as trustee. The fair value of these trust assets, which are reported at the market value of the investments reported by the trustees and adjusted based on the estimated life expectancy of the donor, have been identified as Level 3 in the fair value hierarchy. There were no changes in valuation techniques noted for the year ended December 31, 2021. No amounts were transferred during the year ended December 31, 2021; the only change is attributable to the change in value of \$24,922 for the year ended December 31, 2021. A growth rate of 3% and income rate of 4% has been used in the calculation of the present value of these items. The significant unobservable inputs used in the fair value measurement of the Foundation's Level 3 investments are subject to market risks resulting from changes in the market value of its investments.

Mutual funds and ETFs: Prevent Cancer Foundation's holdings in publicly traded mutual funds consist principally of fixed income and equity securities carried at their aggregate market value that is determined by quoted market prices. Each of these investments can be liquidated daily. Valuation is based on Level 1 inputs within the hierarchy used in measuring fair value.

Prevent Cancer Foundation

Notes to Financial Statements December 31, 2021

Assets measured at fair value on a recurring basis are summarized below as of December 31, 2021:

	Level 1	Level 2	Level 3	Total
Investments				
Money market funds	\$ 2,659,013	\$ -	\$ -	\$ 2,659,013
Fixed income				
Mutual funds - fixed income				
Blackrock Strategic Income	516,800	-	-	516,800
Blackrock Total Return	956,487	-	-	956,487
Dodge & Cox Income Fund	949,426	-	-	949,426
Metropolitan West Unconstrained Bond Fund	503,841	-	-	503,841
Western Asset Return	939,976	-	-	939,976
Equities				
ETF - equity				
Invesco QQQ Trust	951,259	-	-	951,259
iShares MSCI EAFE	810,168	-	-	810,168
iShares Edge MSCI Min Vol USA	642,427	-	-	642,427
iShares Russell Mid-Cap Value	-	-	-	-
iShares Russell Mid-Cap Growth	609,283	-	-	609,283
iShares Russell 1000 Value Index Fund	723,946	-	-	723,946
iShares Russell 1000 Growth Index Fund	1,545,980	-	-	1,545,980
Vanguard FTSE Emerging Markets	234,440	-	-	234,440
Wisdomtree US Quality	551,578	-	-	551,578
Mutual funds - equity				
Federated Hermes Small Cap	521,891	-	-	521,891
Lazard Global Listed Infrastructure	464,232	-	-	464,232
MFS Value Fund Class I	681,316	-	-	681,316
T Rowe Price Growth Stock	369,688	-	-	369,688
T. Rowe Price Value Fund Inc	534,173	-	-	534,173
Mutual Funds				
Blackrock Global Allocation	603,161	-	-	603,161
Interests in remainder trusts	-	-	285,026	285,026
Deferred compensation plan				
Equities - AB Wealth Appreciation	506,139	-	-	506,139
Total assets, at fair value	\$ 16,275,224	\$ -	\$ 285,026	\$ 16,560,250

14. Liquidity and availability

The Foundation strives to maintain liquid financial assets sufficient to cover 90 days of general expenditures. Financial assets in excess of daily cash requirements are invested in money market funds and other short-term investments.

See independent auditor's report.

Prevent Cancer Foundation

Notes to Financial Statements December 31, 2021

The following table reflects the Foundation's financial assets as of December 31, 2021, reduced by amounts that are not available to meet general expenditures within one year of the statement of financial position date because of donor or contractual restrictions:

Cash and cash equivalents	\$ 1,748,270
Grants and pledges receivable	348,261
Investments	6,166,816
Total financial assets available within one year	<u>8,263,347</u>

Less amounts unavailable for general expenditures within one year due to:

Restrictions by donors for specific activities or purpose	(1,209,115)
Total financial assets available to meet general expenditures within one year:	<u>\$ 7,054,232</u>

The Foundation's board-designated endowment is subject to annual spending as described in Note 12. Although the Foundation does not intend to spend from the endowments (other than amounts appropriated for general expenditure as part of our Board's annual budget approval and appropriation), the board-designated endowment could be made available if necessary.

15. Related-party transactions

Design services were provided for the Gala by a company owned by a board member. The Foundation paid for a portion of the services during 2020 in the amount of \$37,500. As the 2020 Gala was held virtually, the funds remained in deposits until the year ended December 31, 2021, when they were expensed. The remainder of the fee for services, \$50,462, was paid during the year ended December 31, 2021. Additionally, donated services were provided in the amount of \$85,000 for the year ended December 31, 2021.

During the ordinary course of business for the year ended December 31, 2021, the Foundation paid for legal services from a law firm of which a member of the board of directors is a partner.

16. Allocation of functional expenses and joint costs

The costs of providing the various programs and other activities have been summarized on a functional basis in the statement of activities. Accordingly, certain costs have been allocated among the program and supporting services benefited. The following expenses have been allocated across functional areas based on an estimate of time spent by personnel: advertising, computer services, depreciation, equipment lease, insurance, legal, lodging, maintenance, membership and dues, mileage and parking, temporary services, delivery and shipping, professional services, rent, salaries, payroll taxes and processing, retirement, supplies, taxes and licenses, telephone and internet, and training.

The Foundation incurs joint costs for a newsletter that includes a fundraising appeal insert, website costs, and fundraising activities combined with a programmatic health fair. These costs were allocated based on management's analysis of the content of the newsletter, management's analysis of the number of pages on the website, and the duration of the fundraising component and health fair compared to the total time of the event.

See independent auditor's report.

Prevent Cancer Foundation

Notes to Financial Statements December 31, 2021

Joint allocated costs were as follows for the year ended December 31, 2021:

	<u>Fundraising</u>	<u>Program services</u>	<u>Management and general</u>
Newsletter	\$ 911	\$ 3,947	\$ -
5k run	\$ 695	\$ 2,433	\$ -
Website	\$ 241	\$ 3,676	\$ 52

17. SBA Paycheck Protection Program loan

The Foundation obtained a SBA Paycheck Protection Program loan in the amount of \$374,600 in April 2020 as a result of the COVID-19 pandemic. The Foundation complied with the loan requirements and the loan was forgiven in May 2021.

18. Subsequent events

The Foundation assessed events occurring subsequent to December 31, 2021 through July 5, 2022, the date the financial statements were available to be issued, for potential recognition and disclosure in the financial statements. No events have occurred that would require adjustments to or disclosure in the financial statements.